4528:TYO
Ono Pharmaceutical Co Ltd
JP¥ 2,333.00
arrow_downward
-0.58%(-13.50) Siku 1
1 Okt, 15:30:00 GMT +9 · JPY
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 4528...
Fungua
JP¥ 2,340
Juu
JP¥ 2,349
Chini
JP¥ 2,289
Mtaji wa soko
1.16T
Wastani wa kiasi cha mauzo
1.47M
Kiasi cha mauzo ya hisa
1.61M
Gawio
3.43%
Mgawo wa faida wa kila robo mwaka
JP¥ 20
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
14.38
Juu kwa wiki 52
JP¥ 2,674
Chini kwa wiki 52
JP¥ 1,678
EPS
JP¥ 162
Hisa za wawekezaji
514.12M
Idadi ya wafanyakazi
elfu 4
Fungua
JP¥ 2,340
Juu
JP¥ 2,349
Chini
JP¥ 2,289
Mtaji wa soko
1.16T
Wastani wa kiasi cha mauzo
1.47M
Kiasi cha mauzo ya hisa
1.61M
Gawio
3.43%
Mgawo wa faida wa kila robo mwaka
JP¥ 20
Tarehe ya kutojumuisha gawio
29 Sep 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
14.38
Juu kwa wiki 52
JP¥ 2,674
Chini kwa wiki 52
JP¥ 1,678
EPS
JP¥ 162
Hisa za wawekezaji
514.12M
Idadi ya wafanyakazi
elfu 4
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
www.marketscreener.com
·
saa 18 zilizopita
Ono Pharmaceutical : Venture Investment Relocates to Cambridge, Massachusetts— Accelerating Open Innovation and Maximizing Strategic Returns
Wasifu
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Kuhusu Ono Pharmaceutical Co Ltd
Afisa Mkuu Mtendaji (CEO)Gyo Sagara | Gyo Sagara
Wafanyakazielfu 4.21
Lilianzishwa1717
Makao makuuOsaka, Mkoa wa Osaka, Japani
Sekta-
Tovutiono-pharma.com